Metformin Hydrochloride Syri Pharma

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Syri Pharma, is a biguanide presented as an oral tablet for oral administration. It works by lowering hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity, thereby helping to achieve better glycaemic control in adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Metformin Hydrochloride Syri Pharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity.

Metformin Hydrochloride is an oral antihyperglycemic agent used primarily in the management of disorders related to insulin resistance and elevated blood glucose.

- Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): helps delay or prevent progression to type 2 diabetes. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformin Hydrochloride may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Vitamin B12 deficiency: reduced absorption over long‑term use. - Loss of appetite: decreased desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis, a medical emergency. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: liver enzyme elevations or injury. - Pancreatitis: inflammation of the pancreas. - Hypoglycaemia (when combined with other glucose‑lowering agents): unusually low blood sugar. - Renal impairment worsening: decreased kidney function.

When prescribing Metformin Hydrochloride, clinicians should consider several safety aspects.

- Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Hepatic disease monitoring: avoid use in patients with significant liver dysfunction. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Alcohol consumption: advise limiting intake to reduce lactic acidosis risk. - Vitamin B12 monitoring: check levels during long‑term therapy. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): may increase toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - Beta‑blockers: may mask hypoglycaemia symptoms. - Thyroid hormones: may require dose adjustments.